BR112023000675A2 - Terapia de combinação para tratamento de crescimento celular anormal - Google Patents

Terapia de combinação para tratamento de crescimento celular anormal

Info

Publication number
BR112023000675A2
BR112023000675A2 BR112023000675A BR112023000675A BR112023000675A2 BR 112023000675 A2 BR112023000675 A2 BR 112023000675A2 BR 112023000675 A BR112023000675 A BR 112023000675A BR 112023000675 A BR112023000675 A BR 112023000675A BR 112023000675 A2 BR112023000675 A2 BR 112023000675A2
Authority
BR
Brazil
Prior art keywords
cell growth
abnormal cell
treatment
combination therapy
antibody
Prior art date
Application number
BR112023000675A
Other languages
English (en)
Inventor
Coma Silvia
A Pachter Jonathan
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of BR112023000675A2 publication Critical patent/BR112023000675A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

TERAPIA DE COMBINAÇÃO PARA TRATAMENTO DE CRESCIMENTO CELULAR ANORMAL. A presente invenção se refere a métodos, composições e formas de dosagem oral de um inibidor duplo de RAF/MEK em combinação com um anticorpo anti-PD-1 ou um anticorpo anti-PD-L1 para tratar o crescimento celular anormal (por exemplo, câncer).
BR112023000675A 2020-07-13 2021-07-13 Terapia de combinação para tratamento de crescimento celular anormal BR112023000675A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063051320P 2020-07-13 2020-07-13
PCT/US2021/041439 WO2022015736A1 (en) 2020-07-13 2021-07-13 Combination therapy for treating abnormal cell growth

Publications (1)

Publication Number Publication Date
BR112023000675A2 true BR112023000675A2 (pt) 2023-04-25

Family

ID=79554253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000675A BR112023000675A2 (pt) 2020-07-13 2021-07-13 Terapia de combinação para tratamento de crescimento celular anormal

Country Status (11)

Country Link
US (1) US20230330088A1 (pt)
EP (1) EP4178573A1 (pt)
JP (1) JP2023534009A (pt)
KR (1) KR20230039684A (pt)
CN (1) CN116056699A (pt)
AU (1) AU2021307410A1 (pt)
BR (1) BR112023000675A2 (pt)
CA (1) CA3189383A1 (pt)
IL (1) IL299789A (pt)
MX (1) MX2023000589A (pt)
WO (1) WO2022015736A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116120461B (zh) * 2022-04-29 2023-09-29 德琪(杭州)生物有限公司 新型抗药抗体以及其用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024067631A1 (zh) * 2022-09-30 2024-04-04 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112865A1 (en) * 2014-05-21 2017-04-27 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Also Published As

Publication number Publication date
WO2022015736A1 (en) 2022-01-20
WO2022015736A9 (en) 2022-05-05
US20230330088A1 (en) 2023-10-19
EP4178573A1 (en) 2023-05-17
MX2023000589A (es) 2023-02-13
KR20230039684A (ko) 2023-03-21
CA3189383A1 (en) 2022-01-20
JP2023534009A (ja) 2023-08-07
IL299789A (en) 2023-03-01
CN116056699A (zh) 2023-05-02
AU2021307410A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112023000675A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
BR112022015161A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112023015616A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
MX2020009773A (es) Terapia de combinacion.
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
CL2018000377A1 (es) Mecanismo de resistencia a inhibidores de bromodominio bet
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
CA3183032A1 (en) Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
CO2022000270A2 (es) Inhibidores de enzimas
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer